FYB

EQS-News: Formycon reports results for the first quarter 2023

Retrieved on: 
Thursday, June 1, 2023
Partnership, International, KG, MedImmune, Inc. v. Genentech, Inc., FYB, EBIT, Esselte Leitz GmbH & Co KG, Gesellschaft mit beschränkter Haftung, EBITDA, Euro, Physician, ISIN, CFO, Munich, Security (finance), Tourism

Formycon Group’s revenues increased to a total of Euro 21.5. million in the first quarter of 2023 (Q1/2022: Euro 8.1 million).

Key Points: 
  • Formycon Group’s revenues increased to a total of Euro 21.5. million in the first quarter of 2023 (Q1/2022: Euro 8.1 million).
  • A significant part of revenues resulted from a first milestone payment as part of the commercialization partnership from project FYB202 signed in Q1/2023.
  • „In terms of key figures, the first quarter of 2023 was characterized by various positive special effects.
  • We continue to confirm our guidance for 2023", commented Enno Spillner, CFO of Formycon AG.

Apollo Medical Holdings, Inc. Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 8, 2023
ACO, FYB, California Department of Managed Health Care, California Department, GAAP, EBITDA, Acquisition, Growth, EPS, Conference, The Advisory Board Company, Pharmaceutical industry, Video game, Financial adviser, Health insurance

ALHAMBRA, Calif., May 8, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Net income of $14.3 million for the quarter ended March 31, 2023, an increase of 19%, compared to $12.1 million for the quarter ended March 31, 2022.
  • Net income attributable to ApolloMed of $14.6 million for the quarter ended March 31, 2023, compared to $14.3 million for the quarter ended March 31, 2022.
  • EPS - diluted of $0.31 per share for the quarter ended March 31, 2023, compared to $0.31 per share for the quarter ended March 31, 2022.
  • Segment Results for the First Quarter Ended March 31, 2023:
    Three months ended March 31, 2023

EQS-News: Formycon publishes results for financial year 2022

Retrieved on: 
Friday, April 28, 2023
GMP, Trademark, Partnership, International, Half-life, KG, MedImmune, Inc. v. Genentech, Inc., FYB, European Medicines Agency, COVID-19, Tax, EBIT, Genentech, Esselte Leitz GmbH & Co KG, Gesellschaft mit beschränkter Haftung, EMA, EBITDA, Acquisition, Regeneron Pharmaceuticals, Investment, Patient, Ophthalmology, ISIN, United Kingdom, Depreciation, Biosimilar, Development, HGB, FDA, Pembrolizumab, Annual report, Ustekinumab, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Commercial code, Security (finance), Chemical, Cryptocurrency, Generic drug, Fine chemical, Pharmaceutical industry, Euro

The annual report at Group level is published for the first time in accordance with IFRS (International Financial Reporting Standards).

Key Points: 
  • The annual report at Group level is published for the first time in accordance with IFRS (International Financial Reporting Standards).
  • Furthermore, a toxicity study has been initiated, which results are a prerequisite for entering the clinical development phase.
  • On December 31, 2022, the Formycon Group's financial figures had developed as follows: Group revenues, which in addition to Formycon AG also include the fully consolidated subsidiaries Formycon Project 201 GmbH, FYB202 Project GmbH, Formycon Project 203 GmbH, Bioeq GmbH and the 50% stake in Bioeq AG increased to a total of Euro 42.5 million (2021 IFRS: Euro 36.6 million) in the fiscal year 2022.
  • Formycon AG achieved revenues (HGB) of Euro 28.3 million in the financial year 2022 (2021 HGB: Euro 26.5 million).

EQS-News: Formycon Reports its Nine-month Figures for 2022

Retrieved on: 
Sunday, November 27, 2022
COVID-19, Marketing, Eye, Gesellschaft mit beschränkter Haftung, MedImmune, Inc. v. Genentech, Inc., EBITDA, Teva, Conditional sentence, Patient, ISIN, EBIT, Ophthalmology, Rheumatoid arthritis, Diabetes, Patent, International, HGB, Multiple sclerosis, Cancer, Sale, Press release, Research, Depreciation, Commercial code, FYB, Investment, Forecasting, Acquisition, Euro, Security (finance), Renewable energy, Fine chemical, EU

At the end of the third quarter, the Formycon Groups financial figures were expected as forecast.

Key Points: 
  • At the end of the third quarter, the Formycon Groups financial figures were expected as forecast.
  • Formycon is forecasting revenues at Group level of around Euro 40 million for the whole year.
  • The Formycon Group focuses on research and development for its own, or out-licensed biosimilars projects as well as its own COVID-19 drug (FYB207).
  • For the full year 2022, sales and earnings contributions from the marketing revenues in the additional territories are expected.

DGAP-News: Formycon publishes preliminary figures for the first half of 2022

Retrieved on: 
Tuesday, September 6, 2022
COVID-19, CEO, Pharmacokinetics, Research, Regeneron Pharmaceuticals, Multiple sclerosis, IFRS, WKN, International, Gesellschaft mit beschränkter Haftung, Patient, ISIN, Conditional sentence, EMA, Rheumatoid arthritis, Cancer, MedImmune, Inc. v. Genentech, Inc., Biosimilar, Sale, Genentech, Eye, Severe acute respiratory syndrome coronavirus 2, FDA, Diabetes, EBITDA, Commercial code, Investment, Patent, United Kingdom, FYB, European Commission, Acquisition, Marketing, HGB, Ophthalmology, Tax, EBIT, Depreciation, Royal commission, Security (finance), Fine chemical, Pharmaceutical industry, EU, Euro, Group

On the day of reporting, June 30, 2022, the preliminary key financial figures of the Formycon Group were in line with Formycon's expectations.

Key Points: 
  • On the day of reporting, June 30, 2022, the preliminary key financial figures of the Formycon Group were in line with Formycon's expectations.
  • For the full year of 2022, Formycon continues to forecast revenues above last year's level for the entire Group (2021 IFRS: Euro 37 million).
  • Formycon AG achieved a turnover (HGB) of approximately Euro 12.5 million in the first half of 2022 (H1/2021 HGB: Euro 12.4 million).
  • Dr. Stefan Glombitza, CEO of Formycon AG, comments on the preliminary half-year results as follows: "We are extremely satisfied with the performance in the first half of 2022.

DGAP-News: Formycon AG announces amendment to the proposal for election of a Supervisory Board member (agenda item 9) in the context of the Annual General Meeting on June 30, 2022

Retrieved on: 
Tuesday, June 28, 2022
Supervisory board, Patient, Article, Conditional sentence, Annual, Federal Gazette (Switzerland), Ophthalmology, Marketing, COVID-19, Multiple sclerosis, Cancer, Company, Industry, ISIN, Commercial, Gesellschaft mit beschränkter Haftung, Articles of incorporation, Federal Gazette, Aktiengesellschaft, Eye, Time, WKN, Patent, FYB, Intention, Diabetes, Rheumatoid arthritis, SEC, Health insurance, Security (finance), Property management, Fine chemical, Incorporation, EU

The Supervisory Board of Formycon AG now proposes Dr. Thomas Strngmann for election as a member of the Supervisory Board.

Key Points: 
  • The Supervisory Board of Formycon AG now proposes Dr. Thomas Strngmann for election as a member of the Supervisory Board.
  • The Supervisory Board wants to adhere to the proposed elections to the Supervisory Board in the interests of the Company.
  • In its election of members of the Supervisory Board, the general meeting of shareholders is not bound by nominations.
  • To fill this additional future Supervisory Board position, it is proposed that this Annual General Meeting elect a fourth member of the Supervisory Board.

DGAP-News: Formycon Publishes Annual Financial Statements for the 2021 Financial Year

Retrieved on: 
Thursday, May 19, 2022
AG, Diabetes, HGB, EBITDA, International, Regulation of tobacco by the U.S. Food and Drug Administration, Depreciation, Food, ISIN, FYB, European Medicines Agency, Regeneron Pharmaceuticals, Patient, Investment, Mission statement, Tax, Euro, COVID-19, Consolidated, Marketing, Patent, FDA, Johnson & Johnson, Gesellschaft mit beschränkter Haftung, Commercial code, EMA, Multiple sclerosis, Genentech, KG, Rheumatoid arthritis, Group, IFRS, EBIT, MedImmune, Inc. v. Genentech, Inc., Ophthalmology, Acquisition, Eye, Growth, Biosimilar, Cancer, HOB GmbH & Co KG, CFO, Hand, Development, Security (finance), Generic drug, Pharmaceutical industry, Fine chemical, EU

Press Release // May 18, 2022

Key Points: 
  • Press Release // May 18, 2022
    - Annual result shaped by scheduled investments in FYB202, FYB206 and FYB207
    Munich Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today released its financials for 2021.
  • Due to the increasingly international nature of our business activities, the consolidated financial statements will be prepared in accordance with IFRS (International Financial Reporting Standards) for the first time as of the 2022 half-year financial statements.
  • The separate financial statements of the parent company Formycon AG continue to be prepared and published in accordance with the rules of the German Commercial Code (HGB).
  • Formycon had invested in the development of its own pipeline in the 2021 financial year, resulting in a higher negative annual result compared to previous years.